QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio, is a biotechnology company focused on precision medicine for FGFR-driven diseases. QED is dedicated to developing our investigational candidate drug infigratinib. Infigratinib is a first-class, selective tyrosine kinase inhibitor with encouraging early clinical data in patients previously treated for FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as in preclinical studies of achondroplasia. Future research will explore whether infigratinib has potential in other FGFR-driven tumor types and rare diseases.